HERON THERAPEUTICS, INC. /DE/ Available-for-sale Securities, Gross Unrealized Loss
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Available-for-sale Securities, Gross Unrealized Loss of $10.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2018-02-27
- HERON THERAPEUTICS, INC. /DE/ available-for-sale securities, gross unrealized loss for the quarter ending 2016-09-30 was $16.00K.
- HERON THERAPEUTICS, INC. /DE/ available-for-sale securities, gross unrealized loss for the quarter ending 2016-06-30 was $2.00K.
- HERON THERAPEUTICS, INC. /DE/ available-for-sale securities, gross unrealized loss for the quarter ending 2015-12-31 was $40.00K.
- HERON THERAPEUTICS, INC. /DE/ available-for-sale securities, gross unrealized loss for the quarter ending 2015-09-30 was $0.00.
- HERON THERAPEUTICS, INC. /DE/ available-for-sale securities, gross unrealized loss for fiscal 2017 was $10.00K, a 41.18% decline from fiscal 2016.
- HERON THERAPEUTICS, INC. /DE/ available-for-sale securities, gross unrealized loss for fiscal 2016 was $17.00K, a 57.50% decline from fiscal 2015.
- HERON THERAPEUTICS, INC. /DE/ available-for-sale securities, gross unrealized loss for fiscal 2015 was $40.00K.
- HERON THERAPEUTICS, INC. /DE/ available-for-sale securities, gross unrealized loss for fiscal 2014 was $0.00.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2017-12-31 | $10.00K 10-K · filed 2018-02-27 | |||
| 2016-12-31 | $17.00K 10-K · filed 2018-02-27 | |||
| 2016-09-30 | $16.00K 10-Q · filed 2016-11-08 | $18.00K derived: sum of 2 quarters · filed 2016-11-08 | ||
| 2016-06-30 | $2.00K 10-Q · filed 2016-08-08 | |||
| 2015-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $40.00K derived: sum of 2 quarters · filed 2018-02-27 | $40.00K derived: sum of 3 quarters · filed 2018-02-27 | $40.00K 10-K · filed 2018-02-27 |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-08 | $0.00 derived: sum of 2 quarters · filed 2016-11-08 | $0.00 10-Q · filed 2016-11-08 | |
| 2015-06-30 | $0.00 10-Q · filed 2016-08-08 | $0.00 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-02-19 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |